MAIA Biotechnology Inc./$MAIA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Ticker
$MAIA
Sector
Primary listing
AMEX
Employees
13
Headquarters
Website
MAIA Metrics
BasicAdvanced
$52M
-
-$0.60
0.03
-
Price and volume
Market cap
$52M
Beta
0.03
52-week high
$2.74
52-week low
$1.40
Average daily volume
355K
Financial strength
Current ratio
2.189
Quick ratio
2.028
Interest coverage (TTM)
-347,097.56%
Profitability
Management effectiveness
Return on assets (TTM)
-107.22%
Return on equity (TTM)
-459.53%
Valuation
Price to book
13.05
Price to tangible book (TTM)
13.05
Price to free cash flow (TTM)
-2.697
Free cash flow yield (TTM)
-37.08%
Free cash flow per share (TTM)
-0.59
Growth
Earnings per share change (TTM)
-62.86%
3-year earnings per share growth (CAGR)
-34.50%
MAIA News
AllArticlesVideos
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
Business Wire1 month ago
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
Business Wire2 months ago
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MAIA Biotechnology Inc. stock?
MAIA Biotechnology Inc. (MAIA) has a market cap of $52M as of September 11, 2025.
What is the P/E ratio for MAIA Biotechnology Inc. stock?
The price to earnings (P/E) ratio for MAIA Biotechnology Inc. (MAIA) stock is 0 as of September 11, 2025.
Does MAIA Biotechnology Inc. stock pay dividends?
No, MAIA Biotechnology Inc. (MAIA) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next MAIA Biotechnology Inc. dividend payment date?
MAIA Biotechnology Inc. (MAIA) stock does not pay dividends to its shareholders.
What is the beta indicator for MAIA Biotechnology Inc.?
MAIA Biotechnology Inc. (MAIA) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.